Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | CTRC | Q99895 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 6/20 | 0.43 |
| ▸ | NPY1R | P25929 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26807763 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2CTSKCMA1CTRCNPY4R | |
| Antipain SCHEMBL23132673 | 0.97 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKNPY4RNPY1RCTSB | |
| Antipain SCHEMBL18328611 | 0.97 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKNPY4RNPY1RCTSB | |
| Antipain SCHEMBL642095 | 0.97 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKNPY4RNPY1RCTSB | |
| Antipain SCHEMBL5966873 | 0.97 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKNPY4RNPY1RCTSB | |
| Antipain SCHEMBL14038024 | 0.97 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKNPY4RNPY1RCTSB | |
| Antipain SCHEMBL3280675 | 0.97 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKNPY4RNPY1RCTSB | |
| SCHEMBL17364037 | 0.96 | SMN1; SMN2 (0.64) | SMN1; SMN2CTSKNPY4RNPY1RNPY2R | |
| SCHEMBL17364024 | 0.96 | SMN1; SMN2 (0.64) | SMN1; SMN2CTSKNPY4RNPY1RNPY2R | |
| SCHEMBL20250612 | 0.91 | SMN1; SMN2 (0.60) | SMN1; SMN2CTSKNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590273-B2 | Stabilized glycoside hydrolase variants | NOVOZYMES A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| US-12391934-B2 | Stabilized cellulase variants | NOVOZYMES A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3953463-B1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES AS (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250084394-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2025-03-13 | — | — | US | disclosed |
| US-12129498-B2 | Stabilized endoglucanase variants | NOVOZYMES A/S (DK) | 2024-10-29 | — | — | US | disclosed |
| US-20230295591-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2023-09-21 | — | — | US | disclosed |
| US-20230287380-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2023-09-14 | — | — | US | disclosed |
| US-11661592-B2 | Stabilized endoglucanase variants | NOVOZYMES A/S (DK) | 2023-05-30 | — | — | US | disclosed |
| US-20230143128-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | NOVOZYMES A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| EP-4133066-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | Novozymes A/S (DK) | 2023-02-15 | — | — | EP | disclosed |
| CN-115210371-A | Carbohydrate binding module variants | 诺维信公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220186151-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES A/S (DK) | 2022-06-16 | — | — | US | disclosed |
| EP-3953463-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | Novozymes A/S (DK) | 2022-02-16 | — | — | EP | disclosed |
| CN-113795576-A | Stabilized glycoside hydrolase variants | 诺维信公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20210363510-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2021-11-25 | — | — | US | disclosed |
| US-20210047628-A1 | STABILIZED CELLULASE VARIANTS | NOVOZYMES A/S (DK) | 2021-02-18 | — | — | US | disclosed |
| CN-112272701-A | Stabilized cellulase variants | 诺维信公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-112204137-A | Stabilized cellulase variants | 诺维信公司 | 2021-01-08 | — | — | CN | disclosed |
| US-20200140786-A1 | USE OF ENZYME FOR WASHING, METHOD FOR WASHING AND WAREWASHING COMPOSITION | NOVOZYMES A/S (DK) | 2020-05-07 | — | — | US | disclosed |
| US-20150376554-A1 | Industrial and Institutional Laundering Using Multi-Enzyme Compositions | NOVOZYMES AS (DK) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143128-A1 | CARBOHYDRATE BINDING MODULE VARIANTS | MGAM, MANBA, MAN2B1 | SMN1; SMN2 3210/4885CTSK 1234/4885CMA1 75/4885 |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | IDUA, IDE, TREH | SMN1; SMN2 2305/4885CTSK 1797/4885CMA1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.